SEC Form 4 · accession 0001556327-26-000003
Verrica Pharmaceuticals Inc. · VRCA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John J. Kirby
Officer — Interim CFO
Period of report
Aug 18, 2026
Accepted (ET)
Aug 18, 2026 · 5:00 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001660334
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Aug 18, 2026 | P | 5,000 | $4.93 | A | 23,962 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.85 to $4.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.